» Articles » PMID: 24173814

Permeation and Metabolism of Alternaria Mycotoxins with Perylene Quinone Structure in Cultured Caco-2 Cells

Overview
Journal Mycotoxin Res
Specialty Microbiology
Date 2013 Nov 1
PMID 24173814
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The absorption of four Alternaria toxins with perylene quinone structures, i.e. altertoxin (ATX) I and II, alteichin (ALTCH) and stemphyltoxin (STTX) III, has been determined in the Caco-2 cell Transwell system, which represents a widely accepted in vitro model for human intestinal absorption and metabolism. The cells were incubated with the four mycotoxins on the apical side, and the concentration of the toxins in the incubation media of both chambers and in the cell lysate were determined by liquid chromatography coupled with diode array detection and mass spectrometry (LC-DAD-MS) analysis. ATX I and ALTCH were not metabolised in Caco-2 cells, but ATX II and STTX III were partly biotransformed by reductive de-epoxidation to the metabolites ATX I and ALTCH, respectively. Based on the apparent permeability coefficients (Papp), the following ranking order for the permeation into the basolateral compartment was obtained: ATX I > ALTCH >> ATX II > STTX III. Total recovery of the four toxins decreased in the same order. It is assumed that the losses of STTX III, ATX II and ALTCH in Caco-2 cells are caused by covalent binding to cell components due to the epoxide group and/or the α,β-unsaturated carbonyl group present in these toxins. We conclude from this study that ATX I and ALTCH are well absorbed from the intestinal lumen into the portal blood in vivo. For ATX II and STTX III, intestinal absorption of the parent toxins is very low, but these toxins are partly metabolised to ATX I and ALTCH, respectively, in the intestinal epithelium and absorbed as such.

Citing Articles

Occurrence, toxicity, dietary exposure, and management of Alternaria mycotoxins in food and feed: A systematic literature review.

Zhang Y, Liu C, van der Fels-Klerx H Compr Rev Food Sci Food Saf. 2025; 24(1):e70085.

PMID: 39746866 PMC: 11695269. DOI: 10.1111/1541-4337.70085.


Hazard characterization of Alternaria toxins to identify data gaps and improve risk assessment for human health.

Louro H, Vettorazzi A, Lopez de Cerain A, Spyropoulou A, Solhaug A, Straumfors A Arch Toxicol. 2023; 98(2):425-469.

PMID: 38147116 PMC: 10794282. DOI: 10.1007/s00204-023-03636-8.


In vitro interactions of Alternaria mycotoxins, an emerging class of food contaminants, with the gut microbiota: a bidirectional relationship.

Crudo F, Aichinger G, Mihajlovic J, Varga E, Dellafiora L, Warth B Arch Toxicol. 2021; 95(7):2533-2549.

PMID: 33847775 PMC: 8241668. DOI: 10.1007/s00204-021-03043-x.


Mycotoxins: Biotransformation and Bioavailability Assessment Using Caco-2 Cell Monolayer.

Tran V, Viktorova J, Ruml T Toxins (Basel). 2020; 12(10).

PMID: 33008111 PMC: 7601793. DOI: 10.3390/toxins12100628.


Toxins Synergistically Activate the Aryl Hydrocarbon Receptor Pathway In Vitro.

Hohenbichler J, Aichinger G, Rychlik M, Del Favero G, Marko D Biomolecules. 2020; 10(7).

PMID: 32659980 PMC: 7407958. DOI: 10.3390/biom10071018.


References
1.
Stack M, Mazzola E . Stemphyltoxin III from Alternaria alternata. J Nat Prod. 1989; 52(2):426-7. DOI: 10.1021/np50062a042. View

2.
Yee S . In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth. Pharm Res. 1997; 14(6):763-6. DOI: 10.1023/a:1012102522787. View

3.
Liu G, Qian Y, Zhang P, Dong W, Qi Y, Guo H . Etiological role of Alternaria alternata in human esophageal cancer. Chin Med J (Engl). 1992; 105(5):394-400. View

4.
Stack M, Prival M . Mutagenicity of the Alternaria metabolites altertoxins I, II, and III. Appl Environ Microbiol. 1986; 52(4):718-22. PMC: 239103. DOI: 10.1128/aem.52.4.718-722.1986. View

5.
Schrader T, Cherry W, Soper K, Langlois I . Further examination of the effects of nitrosylation on Alternaria alternata mycotoxin mutagenicity in vitro. Mutat Res. 2006; 606(1-2):61-71. DOI: 10.1016/j.mrgentox.2006.02.008. View